Timothy Tyson - Sep 16, 2022 Form 4/A - Amendment Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
Director
Signature
/s/ Todd Rosenthal, as attorney-in-fact
Stock symbol
SYRS
Transactions as of
Sep 16, 2022
Transactions value $
$0
Form type
4/A - Amendment
Date filed
4/20/2023, 04:41 PM
Date Of Original Report
Sep 19, 2022
Previous filing
Aug 29, 2022
Next filing
Oct 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SYRS Common Stock Award $0 +8K $0.00 8K Sep 16, 2022 Direct
transaction SYRS Common Stock Award +257 +3.21% 8.26K Sep 16, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRS Stock Option (right to buy) Award $0 +12K $0.00 12K Sep 16, 2022 Common Stock 12K $7.35 Direct F2
transaction SYRS Stock Option (right to buy) Award +2.23K 2.23K Sep 16, 2022 Common Stock 2.23K $93.56 Direct F3
transaction SYRS Stock Option (right to buy) Award +1.09K 1.09K Sep 16, 2022 Common Stock 1.09K $199.68 Direct F4
transaction SYRS Stock Option (right to buy) Award +3.29K 3.29K Sep 16, 2022 Common Stock 3.29K $66.18 Direct F5
transaction SYRS Stock Option (right to buy) Award +2.19K 2.19K Sep 16, 2022 Common Stock 2.19K $53.17 Direct F6
transaction SYRS Stock Option (right to buy) Award +2.19K 2.19K Sep 16, 2022 Common Stock 2.19K $26.93 Direct F7
transaction SYRS Stock Option (right to buy) Award +2.85K 2.85K Sep 16, 2022 Common Stock 2.85K $27.84 Direct F8
transaction SYRS Stock Option (right to buy) Award +3.86K 3.86K Sep 16, 2022 Common Stock 3.86K $25.10 Direct F9
transaction SYRS Stock Option (right to buy) Award +3.86K 3.86K Sep 16, 2022 Common Stock 3.86K $7.07 Direct F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Acquired pursuant to the merger agreement between the issuer and Tyme Technologies, Inc. ("Tyme") in exchange for 5,865 shares of Tyme common stock having a market value of $0.3086 per share at the close of trading on September 15, 2022, the last trading day immediately preceding the effective time of the merger, but after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"), with cash paid in lieu of fractional shares.
F2 The option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. Amounts reported in this Form 4 reflect the 1-for-10 reverse stock split effected by the issuer on September 16, 2022.
F3 This option is fully vested and replaced an option to purchase 50,058 shares of Tyme common stock at an exercise price of $4.10 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split.
F4 This option is fully vested and replaced an option to purchase 25,000 shares of Tyme common stock at an exercise price of $8.75 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split.
F5 This option is fully vested and replaced an option to purchase 75,000 shares of Tyme common stock at an exercise price of $2.90 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split.
F6 This option is fully vested and replaced an option to purchase 50,000 shares of Tyme common stock at an exercise price of $2.33 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split.
F7 This option is fully vested and replaced an option to purchase 50,000 shares of Tyme common stock at an exercise price of $1.18 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split.
F8 This option is fully vested and replaced an option to purchase 65,000 shares of Tyme common stock at an exercise price of $1.22 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split.
F9 This option is fully vested and replaced an option to purchase 88,000 shares of Tyme common stock at an exercise price of $1.10 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split.
F10 This option is fully vested and replaced an option to purchase 88,000 shares of Tyme common stock at an exercise price of $0.31 per Tyme share that was assumed in the merger, after giving effect to the Reverse Split.

Remarks:

This amendment to the Statement of Changes in Beneficial Ownership of Securities is being filed to correct the inadvertent omission of the Reporting Person's beneficial ownership of certain securities issued in connection with the closing of the merger with Tyme on September 16, 2022.